Valeant Giving Allergan Until End Of Year To OK $53B Buyout
Valeant Pharmaceuticals International Inc. said it will give Allergan Inc. stockholders until the end of the year to decide on its $53 billion hostile bid for the Botox maker, extending the...To view the full article, register now.
Already a subscriber? Click here to view full article